

Strategic Equity Capital plc

Factsheet commentary – Q3 2025

Past performance is not necessarily a guide to future performance. Portfolio investments in smaller companies typically involve a higher degree of risk. Capital at risk. Extracted portfolio performance is not necessarily indicative of the performance of the fund. Not to be construed as investment advice or recommendation. Views expressed by the investment team are correct at the time of writing but are subject to change.

Overview – Q3 2025

UK equity market performance was mixed in the third quarter of 2025 as smaller company stocks generally underperformed their larger peers. The Deutsche Numis Smaller Companies plus AIM ex-Investment Trusts Index, FTSE AIM All Share, and FTSE 250 Index rose by **2.9%**, **2.0%** and **2.7%** respectively, while the FTSE 100 Index rose by **7.5%** in comparison.

During the third quarter, we observed an inflection in global capital allocation. Over the last three years, outflows from UK equity funds have been recycled into an outperforming US stock market, driving the relative valuation discount of UK equities to multi-decade highs. However, the recently pervasive narrative of US stock market exceptionalism is becoming increasingly fragile: S&P 500 currency-adjusted returns have lagged major global peer indices during the year-to-date; US consumer confidence is weakening; credit card delinquencies and US inflation expectations are rising, and US policy uncertainty with regard to global trade and regional conflicts remains high. All of these factors contributed to \$36.4 billion of outflows from US equity funds over the period – the largest quarterly redemption in over a year.¹ In contrast, European equity funds attracted net inflows, the only major equity region to do so. We believe that the UK, with its strong household and corporate balance sheets, relative political stability, and a services-focused economy insulated from global trade wars, is increasingly well-positioned as a safe haven for international capital.

UK economic fundamentals tell a story at odds with prevailing sentiment. Household and corporate balance sheets remain robust and stronger than G7 peers.² Real wage growth has been sustained for over two years, supporting consumer confidence that now sits above its ten-year average.³ Demand is recovering across discretionary categories with rises in non-essential card spending.⁴ Business sentiment remains elevated compared to recent history,⁵ and the vast majority of our portfolio companies continue to perform

¹ Bloomberg data; Calastone Fund Flow Index, Q3 2025; University of Michigan US consumer confidence data; NY Fed inflation data; NY Fed Household Debt Report data.

² ONS National Balance Sheet, 2024.

³ Bank of England Financial Stability Report, July 2025; GfK Consumer Confidence Index, Q3 2025.

⁴ Barclays Consumer Spending Report, August 2025.

⁵ Lloyds Bank Business Barometer, September 2025.

in-line with or ahead of market earnings expectations (100% in Q3 2025). None of this indicates an economy in distress. Given the solid and improving fundamentals of the UK economy, we see domestic equities as a potentially meaningful beneficiary of capital rotation out of the US in due course. Moreover, while we believe company fundamentals have become mis-priced across the UK equity universe, and more so in the small-cap space, we believe the value of our portfolio companies are generally driven by idiosyncratic factors within management team control, as opposed to wider economic factors. We emphasise that any improvement in UK economic or equity market conditions denotes potential upside to our current return expectations, which are not reliant on portfolio re-rating.

Equity capital markets (ECM) activity, combined with our observations of rising deal flow, corroborate the improving outlook for UK equities, particularly for the smaller companies space. In Q3 2025, UK companies raised £1.5 billion of additional capital (i.e. non-IPO funding), while companies between £250 million and £1 billion market capitalisation raised £269 million – a 93% increase on Q2 2025. A growing number of UK plc management teams from diverse sectors are raising growth capital and often seeking to invest directly within the UK real economy. This activity not only stimulates economic growth in and of itself but reflects rising corporate and investor confidence in the return opportunities available.

While we see upside for UK equities as the economic and stock market backdrop improves, we remain focused on the Fund's bottom-up and private equity-led investment approach. Our high-conviction stock selection and portfolio management style emphasises company fundamentals which we believe provide insulation from broader economic and geopolitical uncertainty. We seek to invest in high-quality UK companies with capable and aligned management teams, structural market drivers, solid and defensible market positions, high-quality earnings streams such as recurring revenues, high margins, and resilient balance sheets.

Performance – Q3 2025

The Trust's NAV Total Return increased by **6.6%** over the quarter ended 30 September 2025, significantly outperforming the FTSE Small Cap Index (excluding Investment Companies)⁶ which decreased by **0.1%**.

Key contributors to returns in the quarter came from: **Diaceutics (+2.0% CTR)**, following interim results that highlighted strong revenue momentum, the signing of new enterprise-wide agreements, and continued adoption of its DXRX platform, which reinforced confidence in its return to profitability and strengthened visibility over future recurring revenues; **Everplay (+1.9% CTR)**, following interim results which upgraded full-year earnings guidance, driven by strong performance of the quasi-recurring revenue back-book of historic video games titles; and **TruFin (+1.8% CTR)**, following sequential earnings upgrades driven by independent video games label, Playstack.

The main detractors in the period were: **Iomart (-1.3% CTR)**, following a major profit warning driven by elevated churn in the self-managed infrastructure segment, driving higher leverage close to banking covenant thresholds. The team is actively pursuing value recovery initiatives on this asset; **Costain (-0.9% CTR)**, despite interim results in-line with market expectations on operating profit and which demonstrated strong orderbook growth, potentially masked by lower revenues due to a decline in transportation and HS2-

6. Where holdings' returns are stated, please note these are Total Returns, including dividends, for each of those stocks over the quarter

related revenues; and **XPS Pensions (-0.5% CTR)**, on no specific newsflow during the period.

Portfolio activity

We made three new investments during the quarter, into; **ActiveOps**, a leading enterprise software provider specialising in back-office management which is led by a high-quality Exec Chair, operating in a structurally expanding market with a dominant position, and benefitting from attractive SaaS financial characteristics, including c.90% recurring revenue, double-digit organic growth, and strong cash flow generation; **Watkin Jones**, a property development business with leadership positions in the build-to-rent and purpose-built student accommodation sectors in the UK, deploying a capital-light forward funding model with a strong balance sheet, and which is poised to benefit from gradual recovery in the forward funding environment, with the potential to re-rate materially from its c.3x EV/EBITDA valuation; and **Spire Healthcare**, the UK's largest private hospital group by revenue, which operates in a structurally attractive UK private healthcare market, is executing on a clear strategy to grow profit per theatre, is cutting costs materially to expand operating margins, is building a scaled primary care business to drive referral income into the higher margin hospital business, and whose equity trades at a substantial discount to the freehold value of its property portfolio.

The team also made several follow-on investments, including into; **Diaceutics**, capitalising on a period of share price weakness in spite of strong results delivery and fundamental value proposition; and **Next 15**, following progress in its strategic simplification programme, including the closure of the loss-making Mach49 subsidiary and the sale of non-core operations, which strengthened focus on higher-margin consultancy activities and reinforced confidence in management's capital discipline and long-term growth outlook.

The Fund made two full exits during the period: from **Inspired** following an all-cash takeover by HGGC, a US mid-market private equity firm, at 81p per share, a 33% premium to the undisturbed share price; and **Benchmark**.

Outlook – Q4 2025

Improving UK economic fundamentals, capital rotation away from overvalued US markets, and accelerating domestic fundraising all contribute to a supportive backdrop for UK equities going forwards. As expected, we continue to see compelling evidence of the UK small-cap returns opportunity in the form of elevated corporate M&A and public-to-private activity, with 38 bids announced year-to-date for companies valued over £100m market capitalisation, representing £33bn of equity value. Average UK bid premia of 40% above undisturbed prices reflect buyers' recognition of undervaluation and their willingness to pay for quality financial or strategic assets despite higher deal funding costs compared to previous years.⁷

It remains an anomaly in our view that trade and private equity buyers see a compelling value opportunity in UK equities, particularly in the smaller companies space – 97% of firm offers for UK-listed companies during the year-to-date came at below £2bn in value compared to an historical average of 82% – yet organic investors have been slow to realise the value opportunity, as reflected in consistent fund outflows. We see improving conditions and the removal of uncertainty around the upcoming Autumn budget as

⁷ Peel Hunt UK M&A Strategy Report, October 2, 2025

potential catalysts for a re-rating of UK smaller company shares and this portfolio.

Moreover, companies that remain listed are responding to undervaluation by deploying strong cash flows into share buybacks at elevated rates. The FTSE 100 buyback yield stands at 39% above its five-year average, the FTSE 250 35% higher, and the AIM 100 184% above trend.⁸ In many instances – for example, Sainsbury's, Balfour Beatty, and TP ICAP across our portfolio – we believe this capital allocation reflects management teams' conviction that their shares represent attractive investment opportunities above the return rates achievable for organic growth projects or M&A activity. For patient investors, share buybacks can create attractive value compounding whereby future equity value creation or income distributions accrue to a smaller pool of investors, improving total returns.

We are increasingly optimistic about the total return opportunity available in the UK smaller companies space. The UK economy is robust, and we are seeing an increasing number of compelling equity value indicators in our space. As a collective, we believe strong UK economic and corporate fundamentals will be recognised in due course, particularly given the waning confidence in US equity market exceptionalism. In the meantime, we continue to focus on executing our bottom-up, private equity-led investment approach, focusing on high-quality companies with clear idiosyncratic value drivers, operating in niche and structurally growing areas of the UK and global economy.

Important information

The information contained in this document (the "Document") is being communicated in the United Kingdom for the purposes of section 21 of Financial Services and Markets Act 2000 and has been issued by Gresham House Asset Management Limited ("GHAM" or the "Manager"). GHAM whose registered office is at 5 New Street, London, EC4A 3TW is a company authorised and regulated by the Financial Conduct Authority (FCA) (no.682776).

The information should not be construed as an invitation, offer or recommendation to buy or sell investments, shares, or securities or to form the basis of a contract to be relied on in any way. GHAM provides no guarantees, representations, or warranties regarding the accuracy of this information. No third-party liability is accepted by GHAM, its members and employees, or its affiliates and their directors, in respect of errors and omissions, other than under the duties and liabilities of the Financial Services and Markets Act 2000. Potential investors are advised to independently review and/or obtain independent professional advice and draw their own conclusions regarding the economic benefit and risks of investing in the securities and legal, regulatory, credit, tax, and accounting aspects in relation to their particular circumstances. The recipient should consult its tax, legal, and accounting or other advisers about the issues discussed herein and shall be solely responsible for evaluating the risks and merits involved in the content of this Document. The value of investments may fall as well as rise and investors may not get back the amount invested. Funds investing in smaller companies may carry a higher degree of risk than funds investing in larger companies. The shares of smaller companies may be less liquid than securities in larger companies. This Document is provided for the purpose of information only and before investing you should read the Prospectus and the Key Investor Information Document ("KIID") as they contain important information regarding the Fund, including charges, tax and fund specific risk warnings and will form the basis of any investment. The Prospectus and KIID are

⁸ Bloomberg data.

available from www.strategicequitycapital.com. Investors are reminded that past performance is not indicative of future results. No person, especially those who do not have professional experience in matters relating to investments, must rely on the contents of this Document. If you are in any doubt as to the matters contained in this Document, you should seek independent advice where necessary. This Document has not been submitted to or approved by the securities regulatory authority of any state or jurisdiction. This Document is intended for distribution in the United Kingdom only. Any dissemination or unauthorised use of this Document outside the United Kingdom by any person or entity is strictly prohibited. Please contact a member of the Gresham House team if you wish to discuss your investment or provide feedback on this presentation. Gresham House is committed to meeting the needs and expectations of all stakeholders and welcomes any suggestions to improve its service delivery.

www.greshamhouse.com | (0) 20 7382 0999